Introduction
Glycogen storage disease type Ib (GSD-Ib, MIM232220) is an autosomal recessive disorder with an incidence of 1 in 500 000 [1, 2] . Predominantly considered a metabolic disorder characterized by hypoglycemia, excessive glycogen accumulation in the liver and kidney, and abnormal metabolic serum profiles, GSD-Ib is also an immune disorder characterized by neutropenia and myeloid dysfunctions [1, 2] . Although the genetic basis of the disease, mutations in the glucose-6-phosphate transporter (G6PT or SLC37A4) gene, is well established [3, 4] , only the metabolic component of the disease is understood biochemically.
Most cells derive their energy from glucose taken up across the cell membrane by diffusion facilitated by the glucose transporters [5] . Inside the cell, glucose is converted to the membrane-impermeable molecule glucose-6-phosphate (G6P) by either hexokinase or glucokinase, trapping the glucose inside the cell. In the tissues responsible for maintaining interprandial blood glucose homeostasisprimarily the liver and kidney -G6P derived from glycogenolysis or gluconeogenesis is transported across the endoplasmic reticulum membrane by the G6PT [1, 2] . Compartmentalized in the endoplasmic reticulum lumen, G6P is hydrolyzed to glucose and released. There are two enzymatically active G6P hydrolases embedded in the endoplasmic reticulum membrane with their active sites facing into the lumen [6] [7] [8] . One, glucose-6-phosphatasea (G6Pase-a or G6PC), is restricted to expression in the liver, kidney, and intestine [1, 2] . The other, G6Pase-b (G6PC3), is expressed ubiquitously [9, 10] . Deficiencies in G6Pase-a cause GSD type Ia (GSD-Ia) [1] . In contrast, deficiencies in G6Pase-b do not cause GSD but were recently shown to cause a severe congenital neutropenia syndrome [11 ] of unknown incidence.
Both G6PT and G6Pase-a must be functionally coupled to transport and hydrolyze G6P to glucose [4, 12] . A detrimental mutation in either protein prevents the other functioning efficiently [1, 2] . Surprisingly, despite the G6PT/G6Pase-a interdependence, GSD-Ia patients do not suffer from immune dysfunctions, while GSD-Ib patients do, suggesting the immune disorders in GSD-Ib reflect the role of G6PT in cells expressing G6Pase-b but not G6Pase-a [10, 13] .
Recently, it was shown that G6Pase-b can couple with the G6PT to hydrolyze G6P to glucose [10, 13] . Mouse lines deficient in G6PT [14] or G6Pase-b [13] have been generated to examine the biology of the G6PT/G6Pase-b complex, revealing that G6P translocation and metabolism in the endoplasmic reticulum are critical for normal neutrophil functions.
Clinical phenotype
Mutations in the G6PT gene of approximately 160 GSD-Ib patients have been studied [3]. All mutations decrease or completely abolish cytoplasmic G6P transport into the endoplasmic reticulum for hydrolysis by G6Pase-a or G6Pase-b, disrupting endogenous glucose production [1,2]. In gluconeogenic organs that coexpress G6PT and G6Pase-a, this disruption leads to the metabolic phenotype common to GSD-Ia and GSD-Ib characterized by hypoglycemia, hepatomegaly, nephromegaly, hyperlipidemia, hyperuricemia, lactic acidemia, and growth retardation [1,2]. Long-term presentations include hepatic adenomas with risk for malignancy and renal failure. In nongluconeogenic organs that coexpress G6PT and G6Pase-b, the impacts of the mutations are less well understood. The most obvious impact is seen in neutrophils, in which the disruption is manifested as neutropenia and neutrophil dysfunction [1, 2, 13, 14] . However, the picture of glucose metabolism that is emerging from these cells suggests there may be ramifications in other tissues that are not yet recognized.
Neutrophils from GSD-Ib patients exhibit impaired mobility, chemotaxis, and calcium mobilization, as well as diminished respiratory burst and phagocytotic activities [1,2, 15, 16] . As a result, recurrent bacterial infections are commonly seen in GSD-Ib patients, and up to 77% of patients manifesting neutropenia also develop inflammatory bowel disease (IBD), indistinguishable from idiopathic Crohn disease [17, 18] . Oral manifestations of GSD-Ib include dental caries, gingivitis, periodontal disease, delayed dental maturation and eruption, oral bleeding diathesis, and oral ulcers [19] . A study evaluating the hypothalamus-pituitary-thyroid axis of seven GSD-Ib patients showed that 57% had thyroid autoimmunity and hypothyroidism [20] . Seronegative myasthenia gravis may be another complication [21] .
In a Collaborative European Study of 57 GSD-Ib patients, 54 suffered from neutropenia. Of these, 64% were first neutropenic before age 1 year, and a further 18% between ages 6 and 9 years [17] . Neutrophil function was examined in 18 neutropenic patients, and all were abnormal [17] . In a medical database of North America that consists of 36 GSD-Ib patients with a mean age of 13.7 years, it was found that IBD was diagnosed at an average age of 8.7 years [18] . All patients with IBD had neutropenia [17, 18] .
Genetics
Human G6PT is a single copy gene consisting of nine exons [4,22] on chromosome 11q23 [23] . There are two alternately spliced transcripts, G6PT [3,4] and the variant G6PT (vG6PT [24, 25] ), which contains an additional exon-7 sequence [4, 22] . G6PT is ubiquitously expressed [26] whereas vG6PT is expressed primarily in the brain, heart, and skeletal muscle [25] . Seventy-nine separate G6PT mutations have been identified in approximately 160 GSD-Ib patients studied to date ([3] http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SLC37A4). These include 32 missense, 11 nonsense, 19 insertion/ deletion, and 17 splicing mutations, which appear scattered throughout the coding and exon-intron junction regions. These mutations show some ethnic variability. In Caucasian patients (216 alleles), c.1042_1043delCT and p.G339C are the prevalent mutations, representing 31 and 14%, respectively. In Japanese patients (38 alleles), p.W118R is the prevalent mutation, accounting for 37%. The number of known alleles in other ethnicities is too low to draw clear statistical conclusions.
Of the 160 patients studied to date, seven patients carrying deleterious G6PT mutations are not reported to have manifested either neutropenia or frequent infections [27] [28] [29] [30] . A genotype-phenotype study with a cohort of 22 GSD-Ib patients carrying 16 different G6PT mutations, including nine patients homozygous or compound heterozygous for nonsense mutations failed to show any correlation between individual mutations and the presence of neutropenia, bacterial infections, and systemic complications [28] . Although these numbers are low, they do suggest there may be modifiers that can compensate for or stabilize low-level expression in vivo.
Function of the glucose-6-phosphate transporter protein
Human G6PT and vG6PT are hydrophobic proteins composed of 429 and 451 amino acids, respectively [3,4, 24, 25] . Human G6PT is anchored in the endoplasmic reticulum by 10 transmembrane domains [31, 32] (Fig. 1 ). G6P transport across the endoplasmic reticulum membrane and G6P hydrolysis in the endoplasmic reticulum lumen are tightly coupled processes, with G6Pase-a activity required for efficient G6P transport [4, 12] . In the absence of G6Pase-a activity, there is only a low basal level of G6P uptake activity [4] . A G6P transport activity assay has been developed based upon cells coexpressing both G6PT and G6Pase-a [4, 33, 34] . Using this assay, mutations identified in the G6PT gene of GSD-Ib patients were shown to decrease or completely abolish G6P transport activity, establishing the molecular basis of this disorder [4, 33, 34] . The vG6PT also functions as a G6P transporter [25] , though little more is known of this transporter.
G6PT belongs to the organophosphate:phosphate antiporter family of the major facilitator superfamily [35] . Using reconstituted proteoliposomes expressing only G6PT, G6PT was shown to be a phosphate-linked antiporter transporting G6P into the endoplasmic reticulum lumen and phosphate out [36 ,37] .
Treatment and prognosis
The metabolic abnormalities of GSD-Ib can be adequately controlled with dietary therapies [38] [39] [40] that maintain normoglycemia and enable patients to attain near normal growth and pubertal development, with fewer complications as they age. However, dietary therapies fail to improve myeloid functions. For patients exhibiting persistent, therapy-refractory hypoglycemic episodes, more invasive therapies have been investigated. In seven GSD-Ib patients, orthotopic liver transplantation (OLT) was assessed [41] [42] [43] [44] [45] [46] , and, in one patient, hepatocyte transplantation was performed [47] .
Both transplantations improved the metabolic abnormalities for all patients. Of the seven patients receiving OLT, five showed persistent neutropenia following transplantation [41, 42, 45, 46] , but three patients reported less frequent infectious episodes [45, 46] . For the two patients in whom OLT resolved neutropenia [43, 44] , one exhibited improved myeloid function, evidenced by decreased infectious episodes and gastrointestinal symptoms, and normalized neutrophil function [44] . How the transplants corrected the immune functions is not clear. Secondary effects such as 'microchimerism', in which donor-derived leukocytes, present in the transplanted organ, migrate to the recipient's bone marrow and assume their original function, cannot be ruled out [48] . Indeed, Adachi et al. [44] detected 5% of chimerism in the recipient leukocytes. The studies do suggest that a good metabolic control is beneficial for neutrophil function of GSD-Ib patients.
GSD-Ib patients, manifesting neutropenia or neutrophil dysfunctions or both that predispose to frequent infections and IBD, are treated by granulocyte colony-stimulating factor (G-CSF) therapy which improves neutropenia and decreases the number and severity of infections [17, 18, 49] . The toxicity of G-CSF therapy, evaluated in a 3-year study consisting of 13 GSD-Ib patients with a mean age of 9.9 years, showed no significant short-term toxicity, though all did develop splenomegaly [50] . One major complication of patients with severe chronic neutropenia receiving G-CSF therapy is myelodysplasia/acute myeloid leukemia Figure 1 Proposed pathways for glucose-6-phosphate metabolism in wild-type, G6pt S/S and G6pc3 S/S neutrophils Glucose transported into the cytoplasm via GLUT1 is metabolized by hexokinase to G6P, which can participate in glycolysis, hexose monophosphate shunt (HMS), glycogen synthesis or be translocated into the lumen of the ER by the G6PT. In wild-type neutrophils, G6P localized within the ER lumen can be hydrolyzed by G6Pase-b and the resulting glucose transported back into the cytoplasm to reenter any of the previously mentioned cytoplasmic pathways. In G6pt À/À neutrophils that lack a functional G6PT, cytoplasmic G6P cannot be translocated into the lumen of the ER, and in G6pc3 À/À neutrophils, which lack a functional G6Pase-b, ER-localized G6P cannot be recycled to the cytoplasm. The GLUT1 transporter, responsible for the transport of glucose in and out of the cell, is shown embedded in the plasma membrane. The G6PT transporters, responsible for the transport of G6P into the ER and G6Pase-b, responsible for hydrolyzing G6P to glucose and phosphate, are shown embedded in the ER membrane by 10 and nine transmembrane helices, respectively. ATP, adenosine triphosphate; ER, endoplasmic reticulum; G6PT, glucose-6-phosphate transporter; NADPH, nicotinamide adenine dinucleotide phosphate; Pi, inorganic phosphate.
(AML) [51, 52] . The French Severe Chronic Neutropenia Registry collected data on 15 GSD-Ib patients; among them 14 patients received a median cumulative duration of 2.8 years of G-CSF therapy, and found no cases of AML [51] . However, three separate studies have reported the development of AML in GSD-Ib patients [53, 54, 55 ] . One did not receive G-CSF therapy [53] whereas the other two received G-CSF over a period of 6 [54] and 14 [55 ] years, respectively. The AML observed following 14 years of continuous G-CSF therapy is a classical monosomy 7 and translocation t(3;8)(q26;q24) [55 ] . This suggests that GSD-Ib patients receiving long-term G-CSF therapy can still develop AML and should receive regular bone marrow examinations.
A recent study has evaluated antioxidant supplementation for GSD-Ib patients using vitamin E [56] . Although patients' neutrophil function did not improve with this therapy, neutrophil counts increased and the frequency and severity of infections decreased, suggesting this might be a beneficial strategy.
The G6PT-deficient GSD-Ib (G6pt À/À ) mice mimic the full phenotype of human patients [14] . Studies using G6pt À/À mice showed that wild-type mice harboring bone marrow transplants from G6pt À/À mice manifest neutropenia and neutrophil dysfunctions [57] . These findings suggest that abnormal G6PT expression in bone marrow and resident neutrophils leads to abnormal myeloid function and that bone marrow transplantation may be considered for treating neutrophil complications in GSD-Ib. Recently, a GSD-Ib patient manifesting severe IBD and recurrent infections was treated by bone marrow transplantation, which improved neutrophil function and the severity of IBD though a mild neutropenia persisted [58 ] . Although an isolated case, the study suggests that myeloid abnormalities in GSD-Ib may improve following bone marrow transplantation.
The feasibility of gene therapy for GSD-Ib has been evaluated using an adenoviral vector carrying human G6PT (Ad-hG6PT) to treat G6pt À/À mice [59] . The study showed that Ad-hG6PT-infusion transiently corrects metabolic and myeloid abnormalities in G6pt À/À mice. Although promising, longer term efficacy studies and extensive safety evaluations are required before proposing that gene therapy may be a viable future option for GSD-Ib patients.
Neutrophil stress and apoptosis underlie myeloid dysfunction in glycogen storage disease type Ib
In the past, the molecular basis of GSD-Ia and GSD-Ib has been framed by defects in the G6PT/G6Pase-a complex following the failure of either G6PT or G6Pase-a [1,2]. Recently, it has emerged that the framework should be in terms of the function of the G6PT/ G6Pase-a complex in gluconeogenic tissues or the G6PT/ G6Pase-b complex in the myeloid tissues. For decades, it was unclear whether the mechanism of immune deficiency in GSD-Ib is due to defects in G6P metabolism or a completely different function of the 'G6P' transporter. In 2003, a second G6P hydrolase activity, G6Pase-b, was identified [9, 10] . Both G6Pase-b and G6Pase-a have similar kinetic properties [10, 60] and topology, with their active sites localized on the luminal side of the endoplasmic reticulum membrane [6] [7] [8] . G6Pase-b also couples functionally with G6PT [10] to form an active complex that hydrolyses G6P to glucose (Fig. 1) . More interestingly, G6Pase-b, such as G6PT, is expressed ubiquitously [9] . On the basis of these, we hypothesized that the G6PT/ G6Pase-b complex may produce endogenous glucose to some extent within the endoplasmic reticulum lumen in nongluconeogenic cells and tissues, including neutrophils, and this endogenous glucose might play a role in neutrophil homeostasis and function [13, 61 ] .
The lumen of the endoplasmic reticulum serves as a critical site for the maturation and assembly of proteins destined for the cell membrane or secretion [62] . When cells experience conditions that alter the endoplasmic reticulum environment such as glucose deprivation, protein folding can be dramatically affected leading to the accumulation of unfolded proteins in the endoplasmic reticulum. This, in turn, activates signal transduction cascades termed the unfolded protein response, characterized by the induced expression of endoplasmic reticulum chaperones [63] [64] [65] . If the stress is prolonged, apoptotic cell death occurs [63] [64] [65] . Therefore, if endogenous glucose production in the endoplasmic reticulum of neutrophils is critical, any deficiency in the G6PT/G6Pase-b complex should lead to endoplasmic reticulum stress and increased apoptosis. Two recent studies [13, 61 ] provide experimental evidence in support of the hypothesis that G6PT-deficient or G6Pase-bdeficient neutrophils, unable to produce endogenous glucose, would manifest enhanced endoplasmic reticulum stress and apoptosis which underlie neutropenia in these genetic disorders. One study showed that neutrophils from G6Pase-b-deficient (G6pc3 À/À ) mice which are unable to hydrolyze endolumenal G6P to glucose (Fig. 1 ) manifested enhanced endoplasmic reticulum stress and apoptosis [13] . The second study delineated the underlying cause of GSD-Ib using G6PT-deficient neutrophils isolated from G6pt À/À mice that are unable to translocate G6P from the cytoplasm into the lumen of the endoplasmic reticulum (Fig. 1) . The study showed that G6pt À/À neutrophils also exhibit endoplasmic reticulum stress, evidenced by increased production of the molecular chaperons, GRP78, GRP170, and protein disulfide isomerase [61 ] . Consistent with an earlier report, showing that human GSD-Ib neutrophils exhibited an increased rate of apoptosis [66] , the G6pt À/À neutrophils exhibited an increase in apoptotic cell numbers evidenced by increased annexin V binding and caspase-3 activation [61 ] .
In neutrophils, apoptosis is exquisitely regulated. Neutrophil apoptosis can be initiated by two main pathways, the extrinsic death receptor pathway that responds to extracellular stimuli and the intrinsic mitochondrial pathway that is controlled by the Bcl-2 family proteins [63] . The mitochondrial pathway is predominant during spontaneous neutrophil apoptosis [67] . Recent studies suggest that neutrophil apoptosis in G6pt À/À neutrophils results from increased oxidative stress mediated, at least in part, by the intrinsic pathway [61 ] . In G6pt À/À neutrophils, reactive oxygen species (ROS) production is stably elevated relative to the control neutrophils, despite the induction of Mn-superoxide dismutase [68] expression. Another contribution to ROS production in G6pt À/À neutrophils may be via the oxidation and reduction of disulfide bonds in the endoplasmic reticulum [63, 69] as a result of upregulation of protein disulfide isomerase that catalyzes thiol-disulfide exchange. The levels of Bax [70, 71] are elevated in the mitochondrial membrane of G6pt À/À neutrophils over those seen in the control neutrophils. Consistent with this, membrane permeability increased and correlated with the release of both Smac/Diablo and Omi/HtrA2 [72] [73] [74] into the cytosol of G6pt À/À neutrophils. The activation of both caspase-3 and caspase-9 is also greater in the G6pt À/À neutrophils. Therefore, the intrinsic pathway is implicated strongly in the apoptosis seen in the G6pt À/À neutrophils [61 ] . The similarities seen between G6pc3 À/À [13] and G6pt À/À [61 ] neutrophils argue strongly that neutrophil dysfunction seen in GSD-Ib is not a result of a novel activity of G6PT in nongluconeogenic organs but rather a deficiency in endogenous glucose production caused by a defective G6PT/G6Pase-b complex (Fig. 1) .
The question remains why endogenous glucose production via the G6PT/G6Pase-b complex is vital for normal neutrophil functions. Clearly, neutrophils lacking a functional G6PT are different from normal neutrophils. When neutrophils from normal individuals are incubated in the presence of extracellular glucose, their intracellular concentration of G6P increases 4.8-fold [75] . In contrast, neutrophils from GSD-Ib patients have a G6P level 73% that of control cells, and accumulate only 1.6-fold more when incubated in glucose [75] . As a result, G6P levels in neutrophils of GSD-Ib patients remained lower than those in neutrophils of normal individuals, being only 25% of the control level in the presence of glucose. Neutrophils require a constant supply of glucose for function/survival but are unable to produce glucose via gluconeogenesis [76] . Glucose in neutrophils is supplied primarily by uptake from the blood. Neutrophils from GSD-Ib patients have a decreased rate of glucose transport [77] , which could explain the reduction in G6P accumulation in response to glucose, but the role of the glucose transporter has not been elucidated. Future studies should be directed toward the role of the G6PT/G6Pase-b-mediated endoplasmic reticulum uptake and hydrolysis of G6P in energy homeostasis and normal function of neutrophils.
Conclusion
GSD-Ib deficient in G6PT is an inherited genetic disorder that affects metabolic and myeloid functions. The immune deficiency in GSD-Ib is characterized by neutropenia, neutrophil dysfunction, and IBD. G6PT functions as an endoplasmic reticulum G6P transporter that transports cytoplasmic G6P into the lumen of the endoplasmic reticulum for hydrolysis to glucose either by the liver/ kidney/intestine-restricted G6Pase-a or by a ubiquitously expressed G6Pase-b. There is emerging evidence that endogenous glucose production by the G6PT/G6Pase-b complex is essential for normal neutrophil functions. G6PT-deficient neutrophils, unable to produce endogenous glucose, experience enhanced endoplasmic reticulum stress, oxidative stress, and apoptosis, which are responsible for neutropenia manifested by GSD-Ib patients. GSD-Ib neutrophils are impaired in glucose uptake and have reduced intracellular levels of G6P, suggesting that energy metabolism may be impaired, but the molecular mechanism by which G6PT deficiency affects neutrophil functions remains to be elucidated.
